ARCH Venture Partners XIII, LLC purchased $20.0M of KARD (indirect holdings)

ARCH Venture Partners XIII, LLC purchased 1,250,000 indirectly-held shares of Kardigan, Inc. (KARD) at $16.00 ($20.00M total) on 2026-06-22.

Original reporting
SEC EDGAR · ARCH Venture Partners XIII, LLC
Published Jun 24, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KARD
Bullish
medium confidence
Mentioned
$KARD
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KARDBullishLow
01

Why it matters

The newest fact is a $20M open-market purchase by a 10% owner (indirect holdings) at $16.00/share on 2026-06-22, filed on 2026-06-24.

02

Market read

Traders may treat the filing as a modest sentiment tailwind, but it does not introduce new operating or valuation drivers.

03

What to watch

Indirect holdings and the absence of a stated rationale mean traders should avoid over-weighting the signal versus fundamentals and broader tape/volume.

Relevance 8/10Novelty 6/10Timing: filed 2026-06-24; purchase dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for Kardigan, Inc. (KARD).

Company-level read

Ticker impact

$KARDBullishMedium confidence
Context

SEC Form 4 shows ARCH Venture Partners XIII, LLC (10% owner) bought 1.25M KARD shares for $20M on 2026-06-22.

Expected impact

Near-term impact likely limited; could modestly support sentiment if market treats it as a conviction signal.

Evidence & confidence

The filing is primary-source and sizable ($20M), yet it lacks new company-specific operational information (no earnings, trial, contract, or guidance change).

Market effects

Minimal; this is company-specific ownership activity, not a sector-wide development.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is explicitly marked as “No,” but the purchase could still be routine rebalancing or liquidity-driven rather than a new thesis.

Key entities

  • Kardigan, Inc.

    Subject of the Form 4 insider transaction; shares purchased at $16.00/share.

  • ARCH Venture Partners XIII, LLC

    10% owner making an open-market purchase; holdings increased to 15,042,035 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KARDMedAI 8/10

Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollme

$KARDMedAI 8/10

Kardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 Results

Kardigan (NASDAQ:KARD) extends Phase 2 trial of ataciguat, targeting 2027 results. Study finds 27% of mild to moderate patients are fast progressors, with higher risks of valve repair and hospitalization. Cardiac dysfunction prevalent in 80% of patients. Baseline data shows valve calcium as an independent risk marker. Ataciguat's potential effects on valve and heart muscle remain under investigation.

$KARDMedAI 8/10

Kardigan completes enrollment in Phase 2b aortic stenosis trial

Kardigan Inc. (NASDAQ:KARD) completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, enrolling 156 participants. The protocol was amended to assess aortic valve calcium at Week 48. Baseline data showed varying levels of aortic valve calcium and related conditions. Topline data is expected in late 2027. The company also presented findings from a retrospective analysis of aortic stenosis progression.

$KARDMedAI 9/10

Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of…

Kardigan, Inc. (KARD) filed an SEC Form 8-K — Regulation FD Disclosure. PRESS RELEASE Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis Primary endpoint of aortic valve calcium in KATALYST-AV to be assessed at Week 48 alo